Please provide your email address to receive an email when new articles are posted on . Accounting for the presence of multiple, concurrent central lines when calculating central line-associated ...

Acalabrutinib was associated with increased PFS and a 24% reduction in time to next treatment or death in long-term results. Concurrent acalabrutinib, bendamustine, and rituximab (ABR) in the ...

July 24, 2019 (Arlington, VA) -- Below is a summary of a study published online today in Infection Control and Hospital Epidemiology. This article will be freely available for a limited time. SHEA ...

Explore concurrent insurance, where multiple policies cover the same risk simultaneously. Learn how it works, its advantages, and potential challenges.